BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Spero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 11:47 am Sale | 2022-12-31 | 13G | Spero Therapeutics, Inc. SPRO | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -3,411,520 (Position Closed) | Filing |
| 2022-02-14 1:27 pm Purchase | 2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO | BIOTECHNOLOGY VALUE FUND L P | 3,411,520 9.990% | 643,242 (+23.24%) | Filing |
| 2021-02-12 8:16 pm Purchase | 2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO | BIOTECHNOLOGY VALUE FUND L P | 2,768,278 9.990% | 739,873 (+36.48%) | Filing |